# An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

> **NCT00206648** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 271 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Betaferon/Betaseron
- **DRUG:** Betaferon/Betaseron

## Key facts

- **NCT ID:** NCT00206648
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 271 (ACTUAL)
- **Last updated:** 2014-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206648, "An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00206648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*